D2C (direct to consumer) health-tech: How do we help, not hurt, our patients?

3 min read

Direct-to-consumer healthcare. We see it more and more, and it is an increasing trend that’s been written about extensively (see: health-tech business models, the B2C2B playbook, amongst others). Today we want to take a step back and discuss some philosophical implications and the ethical/ safety concerns we think about as investors. And of course, we try never to wax poetic – skip to the end for actionable take-aways that you can use as a founder. Some lessons here translate globally but healthcare is very different in different parts of the world and this post is really focused on the US…....

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Kush Gupta I am a physician and biomedical engineer who is deeply frustrated with the current state of healthcare delivery. Clinically, I am particularly compelled by the medical complexity and humanistic challenges of caring for critically ill patients. In my free-time (depending on the season), I can be found skiing the slopes of Tahoe or kitesurfing out in the Bay.
Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.